According to Zhitong Finance App, China Antibody-B (03681.HK) announced that on December 11, 2025, an SM17 novel drug research application (“IND”) for inflammatory bowel disease (“IBD”) has been submitted to the China National Drug Administration (“NMPA”) Drug Evaluation Center (“CDE”) and has been accepted.

According to Zhitong Finance App, China Antibody-B (03681.HK) announced that on December 11, 2025, an SM17 novel drug research application (“IND”) for inflammatory bowel disease (“IBD”) has been submitted to the China National Drug Administration (“NMPA”) Drug Evaluation Center (“CDE”) and has been accepted.